Esperite N.V. Stocks

0Last Updated 23.03.2026

Issuer Rating

Performance

Poor

Risk

Negligible

Recommendation

Sell

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
0
Key Takeaways

Risk factor

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Esperite N.V., together with its subsidiaries, operates as a regenerative and predictive medicine company in the Netherlands, Spain, Italy, Switzerland, and internationally. It operates through four segments: Stem Cell, The Cell Factory, Genoma, and Other. The company collects, processes, and stores human adult stem cells from the umbilical cord blood and the umbilical cord. It also provides proteomics and genomics predictive medicines; and implements its proprietary technology for clinical grade production of autologous mesenchymal and stromal stem cells. In addition, it develops AGAATA, a diagnostic system based on the next generation sequencing technology, as well as allows laboratories to perform their own genetic analysis with the bioinformatics and methods developed by Genoma. The company's products portfolio includes Tranquility, a non-invasive prenatal test; and Cryosave's whole genome sequencing, carrier screening tests, and other products. Further, it engages in biobanking cord blood and cord tissue stem cells business. The company was formerly known as Cryo-Save Group N.V. and changed its name to Esperite N.V. in July 2014. Esperite N.V. was founded in 2000 and is headquartered in Amsterdam, the Netherlands.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, overvalued

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks